Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.23M Buy
151,875
+14,184
+10% +$661K 0.04% 426
2025
Q4
$6.66M Buy
137,691
+7,322
+6% +$363K 0.03% 405
2025
Q3
$6.11M Buy
130,369
+12,273
+10% +$592K 0.04% 373
2025
Q2
$5.71M Buy
118,096
+18,469
+19% +$944K 0.04% 339
2025
Q1
$5.59M Buy
99,627
+7,988
+9% +$432K 0.06% 276
2024
Q4
$4.43M Buy
91,639
+32,215
+54% +$1.64M 0.05% 299
2024
Q3
$3.43M Buy
59,424
+34,683
+140% +$1.87M 0.07% 261
2024
Q2
$1.2M Buy
24,741
+14,979
+153% +$723K 0.05% 301
2024
Q1
$474K Buy
+9,762
New +$477K 0.07% 276

Other funds holding SNY

&Partners's SNY Position: Q1 2026 in Review

&Partners increased its Sanofi (SNY) stake by 10% in Q1 2026, buying an estimated $661K and bringing the position to 151,875 shares worth $7.23M. The position accounts for 0.04% of the portfolio, ranked #426.

&Partners first reported a position in SNY in Q1 2024 and has held it in 9 quarters since. 737 funds tracked by Wall St. Rank hold SNY as of Q1 2026.

  • &Partners held 151,875 shares of Sanofi worth $7.23M as of Q1 2026.
  • &Partners bought 14,184 Sanofi shares in Q1 2026, an estimated $661K.
  • Sanofi made up 0.04% of &Partners's portfolio in Q1 2026, its #426 holding.
  • &Partners first reported a position in Sanofi in Q1 2024 and has held it in 9 quarters since.
  • 737 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.